About Us
Looking for new forms of life reconstruction
Dengtai Biomedical was established in December 2014, the technology is transferred from Taipei Medical University's "Biomedical Device R&D and Product Pilot Manufacturing Center", invested by the Diamond Fund, with a capital amount of $500 million, to human reconstruction of the medical material development as the goal of the new biotechnology company.
Dengtai Biomedical adopts the cell culture system, 3D printing technology and "Bio-inks" as the basis, aiming to develop the production of customized autologous cellular medical materials. Currently, the company has been conducting relevant trials with many domestic and foreign organizations, and is actively promoting the establishment of relevant domestic laws and regulations, in the hope that 3D bioprinting will have the opportunity to become Taiwan's sophisticated and cutting-edge industry in the international arena.
Dengtai Biomedical Corporation will uphold the innovation and excellence of pioneering technology, develop human tissue and organ reconstruction platforms, and develop exclusive, customized and personalized high-end medical devices to fulfill its mission of professional research, service, care, respect for life, and giving back to the community.
Development of integrated healthcare services
3D Medical Image Reconstruction
Pre-operative 3D medical image reconstruction analysis and 3D printing of pre-operative evaluation models
High-end medical materials for tissue organs
Biological and implantable advanced medical materials for surgical reconstruction of human tissues and organs.
bioink
Bio-Ink Class III Medical Material for Post-Operative Protection and Wound Healing